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Background: Medications for respiratory disorders including asthma and chronic obstructive pulmonary disease
(COPD) are typically delivered to the lung by means of a handheld inhaler. Patient preference for and ability to use
the inhaler may influence their adherence to maintenance therapy, and adherence may affect treatment outcomes.
In this study, patient experience of using a dry powder inhaler (DPI), the ELLIPTA™ DPI, in clinical trials of a new
maintenance therapy for asthma and COPD was investigated. The ELLIPTA DPI has been designed to contain two
separate blister strips from which inhalation powder can be delivered, and to be simple to use with a large,
easy-to-read dose counter.
Methods: Semi-structured, in-depth, qualitative interviews were carried out 2–4 weeks after patients had completed
one of six phase IIIa clinical trials using the ELLIPTA DPI. Interview participants were asked about their satisfaction
with various attributes of the inhaler and their preference for the ELLIPTA DPI relative to currently-prescribed
inhalers, and responses were explored using an inductive content analysis approach. Participants also rated the
performance of the inhaler on several criteria, using a subjective 1–10 scale.
Results: Participants with asthma (n = 33) and COPD (n = 42) reported high levels of satisfaction with the ELLIPTA
DPI. It was frequently described as straightforward to operate and easy to use by interview participants. Ergonomic
design, mouthpiece fit, and dose counter visibility and ease of interpretation emerged as frequently cited drivers of
preference for the ELLIPTA DPI compared with their current prescribed inhaler. Of participants with asthma, 71%
preferred the ELLIPTA DPI to DISKUS™ and 60% to metered dose inhalers. Of participants with COPD, 86% preferred
the ELLIPTA DPI to DISKUS, 95% to HandiHaler™, and 85% to metered dose inhalers. Overall average performance
scores were >9 (out of 10) in participants with asthma and COPD.
Conclusion: The ELLIPTA DPI was associated with high patient satisfaction and was preferred to other inhalers by
interview participants with asthma and COPD. The development of an inhaler that is regarded as easy and intuitive
to use may have positive implications for adherence to therapy in asthma and COPD.
Trial registration: Asthma: NCT01165138, NCT01431950. COPD: NCT01053988, NCT01054885, NCT01009463,
NCT01017952.
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Asthma and chronic obstructive pulmonary disease (COPD)
are chronic respiratory disorders associated with signifi-
cant morbidity and are commonly treated with inhaled
therapies. Despite the availability of effective therapies,
asthma remains uncontrolled in many patients [1]. COPD
is a significant cause of both morbidity and mortality in
later life, the burden of which is predicted to increase
in aging populations [2]. Suboptimal adherence to
maintenance therapies in asthma [3] and COPD [4] in-
creases the burden of these diseases on patients and
healthcare systems.
Maintenance therapy, consisting of an inhaled cortico-
steroid (ICS) alone or in combination with a long-acting
β2 agonist (LABA) is recommended for patients whose
asthma is uncontrolled on ICS alone [5]. ICS/LABA ther-
apy is recommended for patients with moderate-to-severe
COPD and/or history of COPD exacerbation [6]. The in-
haler used to deliver maintenance therapies has a recog-
nised effect on the effectiveness of therapy [7,8]. Patient
satisfaction with the inhaler used to deliver their medica-
tion [9], and their competence in its use [10], have been
identified as modifiable factors that may influence adher-
ence to prescribed treatment. In an analysis of data from
the 3-year TORCH study in COPD, a significant associ-
ation was found between low (<80%) adherence, mortality,
and COPD-related hospital admission [11]. In asthma,
non-adherence to maintenance therapies is common and
may be a factor contributing to poor asthma control [12].
The ICS fluticasone furoate (FF) has been developed as a
monotherapy for asthma, and in combination with the
LABA vilanterol (VI) as a once-daily inhaled maintenance
therapy for asthma and COPD. Currently available ICS/
LABA combination therapies require twice-daily dosing.
By simplifying the dosing schedule, a shift from twice-daily
to once-daily treatment may have a beneficial effect on
treatment adherence [13,14]. However, a range of other
factors are hypothesised to contribute to treatment adher-
ence in asthma [15] and COPD [16]. FF/VI is delivered via
a new dry powder inhaler (DPI), the ELLIPTA™ DPI. The
inhaler is not yet in use in clinical practice and as such has
no real-world test experience. In view of the potential ef-
fects of the perception of the delivery device on treatment
adherence [8,17], we considered it to be clinically import-
ant to gain a better understanding of patients’ attitudes to-
wards the ELLIPTA DPI.
To this end, an exploratory, qualitative study was per-
formed in a subset of patients with asthma and COPD
who participated in phase III trials of FF/VI or FF mono-
therapy and were subsequently interviewed about their
experience of using the ELLIPTA device. Through con-
ducting this study using an inductive methodology, we
aimed to identify any hitherto unanticipated patient-
perceived issues with the ELLIPTA DPI, and to gain anunderstanding of the circumstances under which those
issues arose. We also sought information around pa-
tients’ thoughts on specific attributes of the inhaler and




Patients who completed all study and follow-up visits in the
following phase III trials of FF/VI or FF in COPD:
HZC112206 [ClinicalTrials.gov: NCT01053988], HZC112207
[NCT01054885], HZC102871 [NCT01009463], HZC102970
[NCT01017952]; or asthma: HZA106827 [NCT01165138],
FFA114496 [NCT01431950], were eligible to enter the
qualitative study. Patients gave informed consent to par-
ticipate in this qualitative study at the final or penultimate
scheduled clinic visit. One-on-one in-depth interviews
were conducted by telephone in order to gather informa-
tion on participants’ perception of and satisfaction with
the ELLIPTA DPI. To ensure that the patients would
be able to accurately recall their experience with the
ELLIPTA DPI, the interview was conducted within 4 weeks
of the individual participant completing all trial proce-
dures. Interview participants were paid a fee of US $100 to
compensate them for the time and inconvenience associ-
ated with study participation.
Participants
All interview participants were recruited from study sites
in the USA (asthma: CA, FL, OR; COPD: AL, FL, IN,
NC, OH, OR, SC, TX), were ≥18 years of age, had
English as their primary language, could read English to
an acceptable level, did not have any hearing impairment
that could affect the interview, and had high-speed inter-
net access or could receive express mail materials to aid
discussion as necessary. Patients meeting these eligibility
criteria and completing one of the clinical studies listed
above within the recruitment time period were approached
regarding participation in the interview-based study. The
recruitment sample was thereby determined by the num-
bers of patients at eligible study sites who completed one
of these clinical studies and consented to participate in in-
terviews. Further details of the clinical studies from which
participants were recruited, including the primary end-
points of the studies, are provided in Additional file 1:
Table S1.
Qualitative interviews
Qualitative interviews followed a semi-structured format
based upon a discussion guide (Additional file 2) and fo-
cused only on the participant’s experience with the
ELLIPTA DPI during the clinical study; participants were
not asked about the study treatments. The discussion
guide was developed to build on exploratory qualitative





(n = 33) (n = 42)
Age, years 41 61
Duration of disease, years 22.1 7.1
Self-reported disease severity, 1–10 scale* 5.0 5.6
Current inhaler†
DISKUS only, n 21 11
HandiHaler and DISKUS, n N/A 10
HandiHaler only, n N/A 10
MDI/HFA, n 10 11
DPI (other than DISKUS), n 2 N/A
All data are mean values unless otherwise stated.
*Qualitative scale: 1 = least severe, 10 =most severe.
†Inhaler used to deliver maintenance therapy.
COPD = chronic obstructive pulmonary disorder; DPI = dry powder inhaler;
HFA = hydrofluoroalkane (propellant); MDI = metered dose inhaler.
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and was approved as part of the protocol. Interviews
were approximately 45 min in duration and consisted
of three parts:
1) Introduction: general questions about the
participant’s asthma or COPD and their previous
experience of inhaler use. Patients were also asked
to describe their disease severity on a 10-point
numerical rating scale [18] (1 = not at all severe,
10 = extremely severe).
2) Inhaler discussion: questions focusing on the
participant’s perception of the ELLIPTA DPI, its ease
of use (including their impressions of the
instructions provided with the inhaler), storage,
transportation, and the participant’s preference for
the ELLIPTA DPI relative to their currently
prescribed inhaler. During this part of the interview,
participants were asked to evaluate the ELLIPTA
DPI, on a 10-point scale (1 = worst, 10 = best), with
respect to several key performance measures.
3) Follow-up questions/probes: exploring specific issues
or queries that had previously been identified, or
had arisen earlier in the interview.
Visual stimuli were used as prompts during the inter-
views (Additional file 3): specifically, images of the plain,
unbranded ELLIPTA DPI used in the clinical trials, the pa-
tient instructions, and illustrations of ways in which users
had been observed to open and grip the DPI. These
images were posted on a secure website to which login
details were provided to the participant in advance of
the interview session, or express-mailed with instructions
not to open sealed labelled materials until instructed by
the interviewer.
The interview-based study was conducted by Strategic
Eye, Inc. on behalf of GlaxoSmithKline. Interviews were
conducted by two researchers employed by Strategic
Eye. Strategic Eye worked directly with the clinical study
sites to arrange interviews with patients who completed
the clinical trial and provided informed consent to par-
ticipate in interviews. All staff involved in the conduct of
the study maintained confidentiality of all collected data,
and any identifiable patient information was erased by
Strategic Eye prior to providing interview reports to
GlaxoSmithKline. The study protocol was reviewed and
approved by Schulman Associates Institutional Review
Board (Cincinnati, United States).
Data analysis
Responses to open-ended questions were transcribed
and an inductive content analysis approach [19] was
applied to the transcripts to identify the concepts and
ideas underlying the comparative preferences and patientperceptions of inhaler attributes. For each set of responses
upon which the content analysis was conducted, an open
coding process was used to determine relevant emerging
themes and subsequently identify clusters within these
themes. Additionally, a qualitative descriptive analysis
technique [20] was used to analyze narrative descriptions
of events, such as those provided by patients who de-
scribed instances of incorrect use of the device. The use of
these methods aided the researchers in understanding hu-
man elements of device use in a way that would not be
identified via a pre-planned hypothesis testing approach.
Numerical data were generated from responses to closed
questions regarding inhaler attributes and preference. No
statistical inference was planned or applied to these data,
which are presented in summary form for descriptive in-




A summary of demographic data for participants with
asthma and COPD is provided in Table 1. Participants
with COPD were typically older than those with asthma
and more likely to suffer from co-morbid conditions, such
as arthritis, and to be using multiple medications each
day. Participants with asthma reported longer duration of
disease since diagnosis, and correspondingly longer and
more varied history of inhaler use. Participant-reported se-
verity of disease was on average moderate (5.0–5.6/10) for
both asthma and COPD.
Findings from interviews: key attributes
Participants reported high levels of satisfaction with
and a very positive experience of using the ELLIPTA
DPI. Each of the key attributes of the DPI, as targeted
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by the majority of participants. The findings of the content
analysis of the responses to these questions, together with
representative quotations for each relevant emergent
theme and cluster, are provided in Table 2. The most fre-
quently encountered themes included simplicity of action,
speed and ease of operation, fit of the inhaler to the hand
and mouthpiece to the lips, and dose count awareness.
Ease of use
Patients had been briefed at the start of the clinical study
by a member of staff at the clinical study site on how to
use the ELLIPTA DPI, often with the aid of a demonstra-
tion inhaler. When asked about their use of the instruction
leaflet, interview participants reported that they had not
needed to refer to instructions or ask follow-up questions
after having been shown how to use the inhaler. During
the free response segment of the interview (prior to the
rating of key attributes), several participants spontaneously
reported on the straightforwardness and intuitiveness of
the use of the DPI, describing the few steps required
(“open and inhale, that’s it: not much to it”) and the time
taken to use the ELLIPTA DPI (“a matter of seconds to
use”). These sentiments were reflected by the findings of
the content analysis of the underlying reasons provided
for rating of the ease of use of the ELLIPTA DPI, and
amount of time taken to use the inhaler (Table 2). Partici-
pants with experience of other DPI use commented on
the similarity of the technique used to operate the
ELLIPTA DPI to that of inhalers such as the DISKUS™.
Dose counter
The dose counter of the ELLIPTA DPI helps to provide
the user with confirmation that a dose has been deliv-
ered from the DPI after they have opened and closed the
cover. Participants reported that the dose counter made
it easy to stay on track with their medication, and pro-
vided an indication of the need to refill. Participants with
poor eyesight also reported that the dose counter was
clearly readable, without the need for corrective lenses
or magnification. The red indicator (which displays
when 9 or fewer doses remain in the DPI) was praised
by several participants as providing a visual reminder to
renew their medication.
Cover
Most participants, particularly those who had previous
experience of using a metered dose inhaler (MDI),
expressed a positive opinion of the cover (or ‘lid’) of the
ELLIPTA DPI, which is opened in order to activate a
dose and uncover the mouthpiece. This cover remains
closed when not in use, protecting the mouthpiece, and
is therefore considered to be hygienic. The most fre-
quently encountered content themes in relation to thecover were easy to open and close (several patients com-
mented that they could open it with one hand), and sim-
ple to operate, with a raised lip which can be slid up
using the thumb. MDI users noted that it is useful that
the cover remains attached to the body of the inhaler, as
opposed to a separate cover which has to be removed
and replaced. Some participants remarked that the cover
dragged, or sprang back slightly when pushed open, but
it was also noted that the inhaler would not open inad-
vertently (e.g. during transit), thereby wasting a dose,
and that it was possible to partially open the DPI with-
out using a dose. Three participants with asthma and
four with COPD did report inadvertently actuating the
DPI during the clinical trial by opening and closing the
cover when they were not ready to inhale a dose, result-
ing in the loss of the dose. This was typically due to be-
coming distracted and accidentally opening the cover
when not wishing to inhale a dose. No participant re-
ported more than one error resulting in loss of a dose
during the clinical trials.
Inhalation
Delivery of medication from the ELLIPTA DPI is
achieved by first opening the cover to actuate the dose,
then inhaling the medication from the mouthpiece with
a long, steady, deep breath. The mouthpiece of the
ELLIPTA DPI was reported to be comfortable and well-
shaped and to create a good seal with the lips during
use. Several participants commented that the mouth-
piece increased their confidence that they were receiving
a full dose of the medication relative to other inhalers
they were currently using. Inhalation itself was described
as easy. A frequently-encountered response theme, par-
ticularly among participants with COPD, was that the
medication can be drawn out of the DPI with a shallow
breath. Many participants described being able to feel
the powder while inhaling, which provided confirmation
that they had received a dose, although some asthma pa-
tients expressed preference for a propelled inhaler. A
small minority of participants with experience of using
an MDI or HandiHaler™ felt that the mouthpiece of the
DPI was too short/small.
Handling and storage
Most participants reported finding the handling of the
ELLIPTA DPI to be comfortable and intuitive. Partici-
pants commented positively on the ergonomics of the
inhaler, with the DPI’s fit to the hand, grip and compact
size emerging as frequently cited themes. Most partici-
pants used two-handed methods to open and close the
cover, either pinching the cover between thumb and
forefinger or pulling it down with the thumb. A few pa-
tients with larger hands used a one-handed method of
opening the DPI. Some participants with COPD and
Table 2 Key attributes of the ELLIPTA DPI: selected quotations from participants with asthma (N = 33) and COPD
(N = 42)
Relevant emergent themes (no. of
COPD/asthma patients reporting)
Relevant quotations to illustrate
theme, COPD patients
Relevant quotations to illustrate
theme, asthma patients
Ease of use
Ease and simplicity (16/17) “Life made less complicated” “It’s straight-forward in its use”
“Very easy” “You really don’t have to think about it, it’s that easy”
“Extremely easy to use” “It a no brainer in how to use”
Simple/Intuitive (9/5) “It’s simple and takes the frustration out of it” “It has a very simple design”
“It’s easy to learn to use” “It is really well thought out”
“Really don’t need instructions to use the device, it’s
very intuitive.”
“You don’t need to be a rocket scientist to
use the device, it’s really very simple”
Simple steps (8/3) “Just flip open the cover and inhale” “Open and inhale”
“One hand, one shot, no thought.” “Pull back the lever and inhale”
Issues with Lever Action (2/5) “Opening is a little difficult, the cover feels
tight when I go to slide”
“Lever drags when I pinch it to slide it open”
“Sometimes the lever would move back a little when
I open it”
Amount of time to use device
Quick/Just seconds (27/21) “Takes no time at all to use” “Less time than any other device”
“I can’t imagine it being any faster to use”
“3 to 4 seconds”
“Only 3 seconds to use, it’s so easy”
“About the same amount of time as my current pump”
“No one will notice I’m using it, it’s so quick. I’m always
on the go and this is a good thing”
“It’s incredibly quick and fast”
Number of steps (5/6) “Open, inhale and close” “Flip, inhale and rinse…you’re done”
“Just a flip and you breathe it in” “Just cock it, breathe and go”
Hand feel of the device
Fits hand (17/13) “I have a small hand and it fits it well” “Fits in my hand nicely”
“It’s the right size and shape to fit my hand” “It has a substantial feel that I like”
Never slipped (12/12) “Never slipped from my hand” “It never slipped so I never dropped it”
“I don’t recall ever dropping it”“It doesn’t slip around when you grab it”
“It never slipped from my hand always felt very secure”
Not too large/compact (11/5) “It’s compact and not bulky” “It’s not that big, which is great”
“It’s not too large, which I like” “It has a compact size that’s good”
Comfortable to hold (7/3) “The feel in my hand is comfortable” “It’s comfortable in my hand”
Easy to hold (6/2) “It’s got a nice curve to it that makes it nice to hold” “It has a texture that helps me to hold on to it”
Like grip/design ridges (2/4) “The ridge marks in the thing help me to hold it” “It has little grippers that I like, ridges; they really help”
Ease of opening/closing device
Easy (9/14) “It’s easy to open with one hand” “It’s obvious what to open and how and there is not
much resistance to push it open and closed”
“Just slides open and closed with little effort”
“It really takes no strength to slide the cap”
Simple (6/14) “Just flip it and it’s open, it’s very easy to do” “Trigger is the cover, it is so easy”
“It’s just a simple operation, you can even do it with
one hand”
“It’s really mistake proof”
“It’s simple to just pull open. It closes the same way.”
Difficult to slide cover (4/3) “Sometimes it may stick a little and I need to push a
little harder”
“Takes a little pressure to open, was not real smooth”
“A little harder to open than Advair” “The lever action was a little gritty from time to time”
No problems (general) (3/3) “Cover never got stuck, never had a problem” “No complications, no troubles”
“There just were no problems”
Grips/ridges/lip (3/3)
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Table 2 Key attributes of the ELLIPTA DPI: selected quotations from participants with asthma (N = 33) and COPD
(N = 42) (Continued)
“I can slide it over with my thumb. I use the little
raised lip to push it over”
“I like the flare ups on the cover, makes it easier to open
and close”
Feel of device when placed to the lips
Fits well/seals well (14/17) “It’s shaped like my lips so I felt I got a good seal” “It fits well, there is more of it to fit to my lips”
“Fit my lips perfectly” “Easy to make a tight seal to be sure inhaling the
medicine, and not air.”
“It seals better than others and I feel I get more
of the medicine. I feel I’m getting the full dose.”
“Fit nicely to my lips”
Comfortable (12/9) “It felt right” “It was comfortable, I didn’t have to purse my lips”
“It felt really good to hold it up to my lips” “Just very comfortable”
“It felt very comfortable”
Placement of lips (3/2) “I feel it is a little too small or short, I need to get
my mouth around it.”
“The mouthpiece is a little shallow, I put my mouth
further up”
Ease of activation
Works even with small breath (14/5) “Worked even when my breath was shallow” “I had no problem breathing in the medicine on days I
could breathe, it was effortless”
“It was not hard to draw out the medicine”
“I didn’t feel I needed to suck as hard” “I think it takes less breath to get the medicine in”
“One big inhale and I know I got the medicine”
Easy (4/11) “Less difficult than an MDI” “Almost too easy, I called my doctor to make sure I was
doing it right”
“Very easy to inhale” “It was just real easy to do”
Medicine delivery (7/7) “I could feel the medicine. I could feel the powder
going in”
“I could feel the air flowing through so I knew
something was happening”
“I just felt like I got all the medicine” “Felt like I could feel the medicine and it was easy to
direct it to the back of the mouth”
Not propelled (0/4) “I would like it better if it was propelled”
“Don’t feel it the same way as a pump. I have no proof
it’s working or dispensing.”
Use and value of dose counter
Big/easy to see/read (17/19) “I can see the red indicator even without my
glasses”
“The black and white numbers are very easy to see”
“I can read the numbers without my glasses” “I can see them without my glasses”
“I don’t need to pull out my magnification to see
the numbers”
“The numbers are big and easy to read”
“It’s large enough I can see it”
Keeps me on track (12/6) “Indicates to me when doses are getting low” “Keeps me on track with my medicine”
“Makes it easier for me to keep up and not forget” “Helps me know if I took my medicine each day
“It’s easy to read. It tells me when to refill. And, I
know if I took my medicine”
“I like to know if I missed a day, and this helps me
Red indicator (8/7) “The red indicator tells me I’m close to being out
of medicine”
“The red strip tells me when I’m low”
“9 or less and it goes to red and tells me I’m getting
close to being out of medicine”
“I like that it turns red when getting low, I know to
reorder.”
“I like the red indicator”
Helpful (6/6) “It has actual numbers and that’s helpful, no
guessing”
“It’s simply helpful”
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ficulties with the opening and closing of the DPI during
worsening of arthritis symptoms. However, these partici-
pants also reported that the ergonomic design and ridged
cover meant that they were able to slide open the ELLIPTA
DPI without having to grip the cover. In addition, the
ridged side grips were considered by participants to de-
crease the likelihood of the inhaler slipping from the hand.
In terms of storage, participants reported that the ELLIPTA
DPI is small enough to be carried in a pocket or purse, and
that the flat base aids the storage of the inhaler by enabling
it to stand unsupported.
Preference relative to other inhalers
A summary of participants’ preference for the ELLIPTA
DPI relative to other inhalers is provided in Table 3. The
majority of participants with asthma and most partici-
pants with COPD preferred the ELLIPTA DPI to the in-
haler(s) used to deliver their current medication (as
prescribed after the end of the clinical study from which
they were recruited).
The outcomes of inductive content analysis performed
on the reasons given by patients for their preference are
provided for asthma patients (Table 4) and COPD pa-
tients (Table 5).
The ELLIPTA DPI was preferred to DISKUS in over
three quarters of comparisons made by 42 participants
with asthma or COPD. The main drivers of preference
were the simplicity and ease of use of the ELLIPTA DPI;
its ease of handling; size; portability and storage; the
shape of the mouthpiece and seal made with the lips on
inhalation; and the size and visibility of the dose counter.
The mouthpiece seal and ease of handling were the most
prominent response themes among participants withTable 3 Summary of patient preference for the ELLIPTA
DPI relative to specified other inhalers
Comparator device No. of patients using
comparator device
No. (%) of patients
expressing preference
for the ELLIPTA DPI
Total
DISKUS 42 33 (79)
MDI/HFA 30 23 (77)
HandiHaler 20 19 (95)
Asthma
DISKUS 21 15 (71)
MDI/HFA 10 6 (60)
COPD
DISKUS 21 18 (86)
MDI/HFA 20 17 (85)
HandiHaler 20 19 (95)
COPD = chronic obstructive pulmonary disorder; DPI = dry powder inhaler;
HFA = hydrofluoroalkane (propellant); MDI = metered dose inhaler.COPD, whereas the simplicity of operation and storage
and portability of the inhaler were more frequently cited
by asthma patients.
The ELLIPTA DPI was preferred to current MDI by
over three quarters of participants with asthma or COPD.
The most frequently encountered themes underlying pref-
erence for ELLIPTA over MDI included the ease, speed
and simplicity of operation (in particular, that there is no
need to shake or prime the inhaler before use) and that
co-ordination of activation of the DPI with inhalation is
not required; the reduced number of inhalations needed;
the presence of a readable dose counter; the security and
hygiene of the ELLIPTA DPI’s cover; and the comfort and
fit of the mouthpiece.
Assessing COPD participants who were using the
Handihaler at the time of the study, all but one parti-
cipant preferred the ELLIPTA DPI. The main driver of
preference was the simplicity of the mode of action of the
ELLIPTA DPI compared with that of the HandiHaler,
without the need to open a blister pack and insert a cap-
sule into the device ahead of inhalation; and patients’ in-
creased confidence that they received a complete dose of
medication based on the contoured mouthpiece and sim-
plicity of the device design and operation.
Performance scores
Indicative performance scores for the ELLIPTA DPI
were recorded on a scale of 1 (worst) to 10 (best) for
nine separate attributes of the DPI. The scores obtained
using this method are provided to aid the interpretation
of participants’ perceptions of the inhaler that is sup-
ported by the textual context provided, and should be
viewed with caution in light of the small sample sizes
(42 patients with COPD; 33 patients with asthma) from
which they are derived.
Average performance scores in participants with asthma
and COPD were >9 for all nine attributes (Figure 1). Aver-
age performance scores in subgroups of participants with
asthma (Figure 2A–B and Figure 3A–C), following stratifi-
cation by age, severity, duration of diagnosis, and (COPD
only) previous DPI use, were >8 in all but one subgroup-
category combination. The only score of <8, for the ease
of activation attribute, was recorded in the subset of par-
ticipants with COPD who did not have previous experi-
ence in the use of a DPI.
Discussion
Summary of study findings
This qualitative in-depth interview-based study was car-
ried out in a subset of patients (n = 75) who had previ-
ously completed clinical trials of a novel ICS/LABA
maintenance therapy for asthma and COPD. It was de-
signed as an exploratory study that aimed to investigate
patient perception of attributes of the ELLIPTA DPI in
Table 4 Findings of inductive content analysis of inhaler preference responses of interview participants with asthma
Relevant emergent themes
(no. of patients reporting)
Clusters within theme
(no. of raw mentions)
Relevant quotations to illustrate theme
A – DISKUS (N = 21)
Simpler and one less step (13) Ease of use (5) “Simply open, inhale, and close”
“Easy and fool proof”
Less steps or one step (4) “One less movement, don’t need to slide that lever over”
“It’s one less step”
Simplicity of use (4) “Simple, we have enough complexity in our lives”
“Intuitive, easy to figure out how to use”
Size and ease of handling (10) Smaller, more compact (7) “I like the size, it’s smaller”
Fits hand / grip (5) “Fits in my hand more comfortably”
“I like the grooves so it’s not slippery”
Portability and storage (9) Carries / packs well (8) “Small, it fits in my shirt pocket”
“Easy to carry in a pocket”
Stores well (4) “It’s easy to store because it stands up”
“It takes up less space”
Mouthpiece (8) Better seal, ensures delivery (6) “With this mouthpiece I don’t worry about getting my medicine”
“With lip seal I feel I’m getting the full benefit of the medicine”
Comfortable size/shape (3) “The shape makes the mouthpiece more comfortable”
“Mouthpiece is ergonomically designed”
Counter (7) Size (5) “I like the size of the numbers”
“Main reason is the big counter”
Easy to see (3) “I don’t have to squint to see the numbers”
Color (4) Bland / dislike (3) “The color doesn’t stand out”
Diskus is better color (1) “Purple is easier to find and helps me to remember to use”
B – MDI (N = 10)
Coordination (8) No timing inhalation (4) “I don’t have to worry about timing”
“I have more control over getting the medication”
Does not propel the medication (4) “It doesn’t shoot out the medicine”
“I like the propellant because it pushes the medicine where
it needs to be”
Mouthpiece (5) Good fit / good seal (3) “Fit my mouth well”
“Fit well”
Mouthpiece size (2) “It’s not a bulky size”
Ease of Use (5) Ease (4) “Very easy to use”
“Well thought out to make it easy”
Intuitive (1) “Very easy and obvious what to do”
Dose counter (4) Plan and keep track of doses (2) “Counter helps me to plan ahead”
Easy to read counter (2) “I like the counter is better, it’s bigger and easier to read”
One piece cover (3) One piece construction (2) “Cover is attached and I can’t lose it”
Sanitary (1) “Covers the mouthpiece to keep it clean”
Patients who were using A) DISKUS, B) MDI to deliver their current medication.
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http://www.biomedcentral.com/1471-2466/13/72an inductive manner, and to gather comparative infor-
mation versus other inhalers that had also been used by
the participants. Attributes of the ELLIPTA DPI that
were viewed positively by participants included ease ofuse and simplicity of operation, the visibility and ease of
interpretation of the dose counter, the feel and fit of
the inhalation mouthpiece, and design ergonomics. No
attribute of the inhaler was viewed negatively overall.
Table 5 Findings of inductive content analysis of inhaler preference for interview participants with COPD
Relevant emergent themes
(no. of patients reporting)
Clusters within theme
(no. of raw mentions)
Relevant quotations to illustrate theme
A – DISKUS (N = 21)
Mouthpiece seal and security of
getting all the medication (15)
Security of getting all my medication (8) “I know I’m getting a good seal and all the medication”
“I’m more confident the medication gets where it’s supposed to go”
“With this mouthpiece I know I’m not going to suck air”
Mouthpiece fit/seal to lips (6) “Mouthpiece fits the shape of my mouth”
“I like the mouthpiece and how it fits my lips”
Mouthpiece comfort (2) “Mouthpiece was more comfortable”
More airflow (1) “I found it easier to inhale, I got more air flow”
Ease & comfort to hold and operate (13) Easy/better grip (8) “Has grip lines and makes it easier to hold”
“The bigger top is easier to grip”
Fits well in hand (3) “More slim, it fits nicely in my hand”
Can operate with one hand (3) “Easier to flip open and can do it with one hand”
More comfortable to hold (2) “Feels comfortable when it’s in my hand”
Simple, less steps to operate (13) One less step—saves time (8) “One motion, no extra steps to open”
“One less step”
Easier/simpler to use/user friendly (7) “Easier, no extra step”
“85% easier to use”
Counter makes it easy to read dose (10) Easy to see/read/don’t need glasses (5) “Can glance at it and see the dose count”
“I don’t need to put on my glasses to see it”
Larger counter (4) “Like it because it has a larger dose counter”
Informs me when low (2) “Gives me knowledge of when I’ll run out of medicine”
Ease of storage (4) Ability to stand (4) “It’s easy to store because it stands up”
B – HandiHaler (N = 20)
Simple mode of action / Fewer
steps (17)
Simpler / not complex (11) “Takes a lot less time to use”
“This is much simpler because I have arthritis in my hands”
Fewer steps / less time (8) “I reach in my bag, grab the new device, open it, breathe and
put it back; it’s much less time”
“Just takes less time”
Difficulties managing Handihaler (4) “Spiriva is more difficult, many more steps to manage and more
messy”
Fewer components (7) No capsules (5) “Capsules are a pain in the butt”
“Because there is no pill there is no complication”
No blister pack (3) “I don’t need a scissors to open the package that has the pill
inside, which is good because I have arthritis”
Reliable (6) More assured getting medicine (4) “I wonder if I’m getting all the medication out of the capsule,
and here I don’t have to worry.”
Less chance for error (4) “Less chance for mistakes—this is fool-proof”
“Much less chance of a mistake”
C – MDI/HFA (N = 20)
Ease of operation (8) No shaking/no priming (3) “I don’t have to shake it, I like that.”
One puff, not two (3) “It’s easier because I only have to take one puff, instead of two”
Fewer steps (2) “It’s just fewer steps to take”
Coordination (7) Ease of operation (3) “It’s easy because I have arthritis and I could pull down the cover
(on ELLIPTA), it can be difficult to push down on the other device”
No coordination (2) “It’s simpler to do because there’s no timing to worry about”
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Table 5 Findings of inductive content analysis of inhaler preference for interview participants with COPD (Continued)
Dose counter (4) Has a counter (2) “I like that it has a counter, I don’t think mine does”
Easy to read counter (2) “The counter is bigger and I don’t see as well, so this is good for me”
One piece cover (4) Better cover (4) “This is a better mouthpiece cover, it is much more secure”
HFA = hydrofluoroalkane (propellant); MDI = metered dose inhaler.
Patients who were currently using A) DISKUS, B) HandiHaler, C) MDI/HFA to deliver their current medication.
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http://www.biomedcentral.com/1471-2466/13/72Participants with asthma and COPD expressed prefer-
ence for the ELLIPTA DPI compared with the inhaler
they were using at the time of the study. It should, how-
ever, be borne in mind that the circumstances in which
participants were introduced to and used the ELLIPTA
DPI, within the context of a randomized controlled trial,
inevitably contrasted with their usage of established in-
halers in routine clinical practice.
Inhalers, adherence to medication, and treatment
outcomes in asthma and COPD
The inhaler through which medication is delivered has
been recognized as central to the clinical effectiveness of
any inhaled therapy [8,17]. The ability of the patient toFigure 1 Overall performance scores. COPD = chronic obstructive pulmouse the inhaler correctly is therefore an important factor
in ensuring that the therapy is effectively delivered to
the lung [21]. Suboptimal inhaler technique is associated
with reduced control in asthma and COPD [10] and ad-
dressing incorrect inhaler technique has been the subject
of calls to action in asthma [22,23] and interventional
trials in COPD assessing the best means of educating pa-
tients on inhaler use [24]. The easier and more straight-
forward an inhaler is to use, the lower the likelihood of
inhaler error [22]. COPD patients tend to be older on
average than patients with asthma, more likely to be
regularly taking multiple medications, and more likely to
have physical or cognitive impairments that may impact
their ability to use inhalers correctly [4].nary disorder.
Figure 2 Asthma performance scores by subgroup defined by: A) asthma severity; B) age. Note: asthma severity scores in A range from 1
(not at all severe) to 10 (extremely severe).
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http://www.biomedcentral.com/1471-2466/13/72In addition to correct inhaler technique, adherence is
also a key factor in determining treatment outcomes
[16,25]. Inhaler choice has been hypothesized to play an
important role in influencing whether or not patients ad-
here to their prescribed therapy. In asthma, the use of a
DPI to deliver maintenance ICS has been found to be as-
sociated with improved adherence compared with MDIs
[26]. Adherence to inhaled treatment has previously been
reported to be significantly associated with dosing fre-
quency [27], inhaler technique [28], and patient satisfac-
tion with the inhaler [9], although it should be noted that
the association between satisfaction and adherence is un-
clear [29,30].
Ease of use and handling of the inhaler are important
factors in determining patient satisfaction [31]. The phys-
ical difficulty of handling and using medications has previ-
ously been found to be associated with suboptimal
adherence to COPD medication regimens [32]. In both
asthma and COPD, inhaler characteristics associated with
patient satisfaction include those described in the present
study, namely those pertaining to ease of use such as sim-
plicity of operation, lack of multiple steps, and ease of
learning [33,34].
Because the ELLIPTA DPI has no real-world test ex-
perience and has only been used within the confines of
randomized controlled trials, there are no data in thecurrent scientific literature about patient perception of
the inhaler. The airflow resistance of the ELLIPTA DPI
has however been extensively studied in vitro. In a quan-
titative study, using an Electronic Lung™ breathing simu-
lator [35] to replicate patient-representative inhalation
flow rates, the delivery performance of the DPI was in-
vestigated and showed consistent powder delivery across
a wide range of inhalation parameters. These data sup-
port the suitability of the ELLIPTA DPI for use across a
wide range of disease states, from mild asthma to severe
COPD [36]. Patients were required to demonstrate cor-
rect handling and use of the ELLIPTA DPI to continue
in the clinical trials from which interview participants
were recruited. As such, inhaler technique was not ex-
plored during the present study. Data on patient compe-
tence in use of the DPI, as assessed by study investigators
during three trials of FF or FF/VI, are reported separately
[37]. Ninety-five percent of patients used the DPI correctly
after one demonstration of its usage at randomization.
Study strengths and weaknesses
The results of this exploratory, inductive study, includ-
ing the performance scores, are suitable for qualitative
interpretation. The nature of the study, and the small
number of patients who participated in the interviews,
meant that statistical analysis of or inference from the
Figure 3 COPD performance scores by subgroup defined by: A) COPD severity; B) age; C) prior DPI use. Note: COPD severity scores in
A range from 1 (not at all severe) to 10 (extremely severe). COPD = chronic obstructive pulmonary disorder; DPI = dry powder inhaler.
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http://www.biomedcentral.com/1471-2466/13/72attribute ratings and preference findings would not
have been appropriate. As a retrospective study, it was
not possible to perform a real-time assessment of pa-
tient preferences.The participants in this study were patients with
asthma or COPD who had used the ELLIPTA DPI in a
clinical trial setting and were based in the USA; as such,
the patient group may not have been truly representative
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http://www.biomedcentral.com/1471-2466/13/72of the wider patient population. As a result of the eligibil-
ity criteria for most of the trials from which participants
were drawn, all of the participants had previous experi-
ence of using at least one other inhaler, and almost all
participants were currently prescribed inhaled controller
medication. In view of the possibility of recall bias, inhaler
preference comparisons versus the ELLIPTA DPI are
reported only for the currently prescribed inhaler. The
asthma and COPD participant populations were ad-
equately representative of the broader population in
terms of age.
Patients with lower motivation may be less likely to
have volunteered for the clinical trials than those who
attended all clinic visits and completed a trial (and were
therefore eligible to participate in this qualitative study).
It is also possible that any patients having a strong dis-
like of the ELLIPTA DPI may not have completed the
trial and would thereby be ineligible for participation in
the qualitative research. Study data were anonymised; as
such, only patient-reported information on the severity
of asthma or COPD was available, which may limit the
interpretation of the effect of disease severity on inhaler
preference. Finally, as the ELLIPTA DPI was used to de-
liver treatment to patients in clinical trials, proper in-
struction in correct use of the inhaler was provided, and
patients who were unable to use the DPI correctly were
withdrawn from the trial and would therefore not have
participated in the interviews; however, the incidence of
inability to use the DPI, reported separately, has been
observed to be low [37]. The ease of DPI use reported
here may not be fully realized in real-world clinical prac-
tice if adequate instruction in correct technique is not
provided [38].
Conclusion
The ELLIPTA DPI was preferred over current inhalers by
the majority of asthma and COPD patients recruited from
phase III studies to participate in the post-study inter-
views. Ease of use, simplicity of operation and the design
of the mouthpiece were the most frequently encountered
response themes underlying preference. Whether these
findings from interviews of clinical trial participants will
translate to clinical practice is an important research ques-
tion that warrants further study.
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